- Home
- ETON vs MNPR Comparison
ETON vs MNPR Comparison
Compare ETON & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ETON | MNPR |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 531.6M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ETON | MNPR |
|---|---|---|
| Price | $16.27 | $65.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $29.67 | ★ $97.83 |
| AVG Volume (30 Days) | 211.3K | ★ 276.5K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,316,000.00 | N/A |
| Revenue This Year | $107.23 | N/A |
| Revenue Next Year | $29.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 102.77 | N/A |
| 52 Week Low | $11.09 | $21.00 |
| 52 Week High | $23.00 | $105.00 |
Technical Indicators
Market Signals| Indicator | ETON | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 35.90 |
| Support Level | $16.53 | $63.73 |
| Resistance Level | $17.33 | $74.34 |
| Average True Range (ATR) | 0.64 | 4.42 |
| MACD | 0.08 | -0.47 |
| Stochastic Oscillator | 32.91 | 13.19 |
Price Performance
Historical ComparisonAbout ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.